Our study utilized molecular docking techniques to establish a strong correlation between DACH1, CACNA1D, STARD13 and RUNDC3B and these drugs, suggesting that these genes may serve as promising drug targets for BPH. This evidence concerns the gene DACH1 and benign prostatic hyperplasia.